Maximizing Pipeline Value: How The Accelerator™ Drug Development Model Can Enhance eNPV

Bringing a new therapy to market is increasingly complex, costly, and time-consuming. Drug development programs often require investments of more than $1 billion, take over a decade to reach approval, and face significant risk at every stage. While scientific challenges contribute to these realities, operational complexity is often an equally important factor.

Many organizations still rely on multiple vendors to support manufacturing, clinical research, laboratory services, and supply chain activities. Although this model provides access to specialized expertise, it can also create disconnected workflows, repeated handoffs, and fragmented accountability. As programs transition between vendors, critical knowledge must be transferred, documentation reconciled, and project context re-established, introducing delays and inefficiencies that can impact timelines and increase risk.

The challenge is rarely the performance of individual vendors. Rather, it is the difficulty of maintaining continuity across development stages. When activities are managed within separate systems and organizational structures, coordination becomes more complex, decision-making slows, and valuable institutional knowledge can be lost. As a result, even minor delays can compound over time, extending development timelines and increasing the cost of bringing new therapies to patients.